14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IRWD vs TLPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 35.0/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).
Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 35.0/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both IRWD (35.0/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 76.0); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IRWD vs TLPH. Trailing 12-month operating profitability (IRWD 62.9% vs TLPH -1474700.0%) and valuation multiples (IRWD 12.3x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IRWD vs TLPH Key Questions & Quantitative Answers
As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 35.0/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 35.0/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both IRWD (35.0/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 76.0); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IRWD leads the Growth & Scale pillar: IRWD posts +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, IRWD generates $400M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, IRWD deploys 13.5% of Rev ($54M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.
TLPH screens cheaper on headline valuation multiples. IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRWD (-574.7% ROE) versus TLPH (-143.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.37β · 54% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.